Establishing the First Genetic Variant Registry for Breast and Ovarian Cancer in Colombia: Insights and Implications

Background: Genetic insights from diverse populations are key to advancing cancer detection, treatment, and prevention. Unlike other Latin American countries, Colombia lacks a centralized registry for germline and somatic mutations in breast and ovarian cancer. This study describes the country’s first national variant registry, and the occurrence of recurrent mutations and potential founder effects in Colombia. Methods: To address this gap, we implemented the first capturing protocol using the REDCap system. In a group of 213 breast and/or ovarian cancer patients harboring genetic mutations, we collected genetic, clinical, and demographic data from 13 regional centers across Colombia. Statistical analyses assessed variant distribution and patient demographics. Results: Among 229 identified variants (105 germline, 124 somatic), most were classified as pathogenic or likely pathogenic (72.4% germline, 87% somatic). BRCA1 and BRCA2 accounted for the majority of recurrent mutations. Germline recurrent variants (seen >3 times) were recorded for BRCA1 (77.7%; 21/27) and BRCA2 (22.3%; 6/27). Similarly, recurrent somatic variants were identified for BRCA1 (82.6%; 38/46) and BRCA2 (17.4%; 8/46). Notably, four recurrent variants were previously reported as founder mutations: BRCA1 c.1674del (14.3% germline and 23.7% somatic), BRCA1 c.3331_3334del (33.3% germline and 52.6% somatic), BRCA1 c.5123C>A (52.4% germline and 23.7% somatic), and BRCA2 c.2808_2811del (50% germline and 50% somatic). Most cases originated from the Andean region, highlighting regional disparities. Conclusions: This registry offers the first overview of genetic variants in Colombian breast and ovarian cancer patients. Recurrent and region-specific mutations highlight the need for population-focused data to guide targeted screening and personalized care strategies.

• Publication year

  2025

• Venue

  Diseases

• Publication date

  2025-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/diseases13070222PMID 40710012PMCID 12293925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

  2024cited by this paper
• Cancer statistics, 2023

  2023cited by this paper
• Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis.

  2023cited by this paper
• Specifications of the ACMG/AMP guidelines for ACADVL variant interpretation.

  2023cited by this paper
• Multilocus Inherited Neoplasia Allele Syndrome (MINAS): an update

  2022cited by this paper
• Mutational landscape of cancer-driver genes across human cancers

  2022cited by this paper
• Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

  2022cited by this paper
• Breast cancer incidence among women with a family history of breast cancer by relative's age at diagnosis

  2022cited by this paper
• BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.

  2022cited by this paper
• Breast cancer in Colombia: a growing challenge for the healthcare system

  2021cited by this paper
• Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America

  2021cited by this paper
• Design and establishment of a cancer registry: a literature review.

  2020cited by this paper
• Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis

  2020cited by this paper
• Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis

  2018cited by this paper
• Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients

  2017cited by this paper
• Hereditary cancer syndromes.

  2008cited by this paper
• High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia

  2007cited by this paper

• No citing papers are available for this paper.